Ligand Pharmaceuticals, Inc. (LGND) Reports Q4 Earnings of $0.24, Offers FY12 Sales Guidance
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $285.60 -1.43%
Revenue Growth %: -32.2%
Financial Fact:
Loss from operations: 5.47M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -32.2%
Financial Fact:
Loss from operations: 5.47M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q4 EPS of $0.24, versus $0.12 reported last year. Revenue for the quarter came in at $12.9 million, versus $3.9 million reported last year.
For 2012, Ligand currently estimates total revenues to be approximately $30 million.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.
For 2012, Ligand currently estimates total revenues to be approximately $30 million.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies
- Morgan Stanley Downgrades Sims Metal Management Ltd. (SGM:AU) (SMUPF) to Underweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
